Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model

Nephrology

Volumn 14, Issue 6, 2009, Pages 581-587

  Tominaga, Naoto ^a,c   Robert, Annie ^d   Izuhara, Yuko ^a   Ohtomo, Shuichi ^a   Dan, Takashi ^b   Chihara, Kazuo ^c   Kurokawa, Kiyoshi ^a   Van Ypersele De Strihou, Charles ^d   Miyata, Toshio ^b  

^a TOKAI UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Angiotensin II receptor type 1 blocker; Blood pressure; Optimal dose; Proteinuria; Renoprotection

Indexed keywords

ALBUMIN; TRIACYLGLYCEROL; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERPHAGIA; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENAL PROTECTION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; HYPERTENSION; LINEAR MODELS; MALE; PROTEINURIA; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TETRAZOLES; VALINE;

EID: 69449091003     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01143.x     Document Type: Article

References (46)

1. Mogensen CE. Diabetes and hypertension. Lancet 1979 1 : 388 389.
2. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983 1 : 1175 1179.
3. Feriozzi S, Pierucci A, Roscia E, Cinotti GA, Pecci G. Angiotensin converting enzyme inhibition delays the progression of chronic renal failure in hypertensive patients with immunoglobulin A nephropathy. J. Hypertens. 1989 7 (Suppl 7 S63 4.
4. Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunogloburin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am. J. Kidney Dis. 1994 23 : 247 254.
5. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N. Engl. J. Med. 1996 334 : 939 945.
6. Woo KT, Lau YK, Wong KS, Chiang GS. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int. 2000 58 : 2485 2491.
7. Agodoa LY, Appel L, Bakris GL et al. African American study of kidney disease and hypertension (AASK) study group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA 2001 285 : 2719 2728.
8. Lewis EJ, Hunsicker LG, Clarke WR et al. Collaborative study group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001 345 : 851 860.
9. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan (MARVAL) study investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002 106 : 672 678.
10. Brenner BM, Cooper ME, de Zeeuw D et al. RENAAL study investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001 345 : 861 869. (Pubitemid 34940825)
11. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001 345 : 870 878.
12. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994 37 : 511 516.
13. de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004 110 : 921 927. (Pubitemid 39128617)
14. de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 2004 65 : 2309 2320. (Pubitemid 38670018)
15. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study. Hypertension 2005 45 : 198 202. (Pubitemid 40179960)
16. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003 63 : 1468 1474. (Pubitemid 36350012)
17. Ruggenenti P, Brenner BM, Remuzzi G. Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron 2001 88 : 254 259.
18. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. 'Gruppo Italiano di Studi Epidemiologici in Nefrologia' (GISEN). Kidney Int. 1998 53 : 1209 1216.
19. Laverman GD, Andersen S, Rossing P, Navis G, de Zeeuw D, Parving HH. Renoprotection with and without blood pressure reduction. Kidney Int. 2005 94 (Suppl S54 9.
20. Weinberg AJ, Zappe DH, Ashton M, Weinberg MS. Safety and tolerability of high-dose angiotensin receptor bloker therapy in patients with chronic kidney disease: A pilot study. Am. J. Nephrol. 2004 24 : 340 345.
21. Weinberg MS, Weinberg AJ, Cord R, Zappe DH. The effect of high-dose angiotensin receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. J. Renin. Angiotensin Aldosterone Syst. 2001 2 (Suppl 1 S196 8.
22. Matos JP, de Lourdes Rodrigues M, Ismerim VL, Boasquevisque EM, Genelhu V, Francischetti EA. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy. Clin. Nephrol. 2005 64 : 180 189.
23. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005 68 : 1190 1198.
24. Takaya K, Ogawa Y, Hiraoka J et al. Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat. Genet. 1996 14 : 130 131.
25. Nangaku M, Miyata T, Sada T et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J. Am. Soc. Nephrol. 2003 14 : 1212 1222.
26. Nangaku M, Izuhara Y, Usuda N et al. In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy. Nephrol. Dial. Transplant. 2005 20 : 2661 2669.
27. Ohtomo S, Nangaku M, Izuhara Y, Takizawa S, Strihou CV, Miyata T. Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model. Nephrol. Dial. Transplant. 2008 23 : 1166 1172.
28. Ohtomo S, Izuhara Y, Takizawa S et al. Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. Kidney Int. 2007 72 : 1512 1519.
29. Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: A double-blind randomized cross-over study. Diabetes Care 2003 26 : 150 155.
30. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind crossover trial. Diabetes Care 2003 26 : 2268 2274.
31. Arnlov J, Evans JC, Meigs JB et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham heart study. Circulation 2005 112 : 969 975.
32. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005 293 : 1609 1616.
33. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004 110 : 32 5.
34. Marre M, Lievre M, Chatellier G et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: Randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004 328 : 495 499.
35. Ritz E. Heart and kidney: Fatal twin. Am. J. Med. 2006 119 (5A 315 395.
36. Campbell R, Sangalli F, Perticucci E et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 2003 63 : 1094 1103.
37. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease. Pathophysiology and indications. Kidney Int. 2005 67 : 799 812.
38. Hou FF, Xie D, Zhang X et al. Renoprotection of optimal antiproteinuric doses (ROAD) study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency. J. Am. Soc. Nephrol. 2007 18 : 1889 1898.
39. Gloy J, Henger A, Fischer KG et al. Angiotensin II modulates cellular functions of podocytes. Kidney Int. 1998 67 (Suppl S168 70.
40. Sharma M, Sharma R, Greene AS, McCarthy ET, Savin VJ. Documentation of angiotensin II receptors in glomerular epithelial cells. Am. J. Physiol. 1998 274 : F623 27.
41. Mifsud SA, Allen TJ, Bertram JF et al. Podocyte foot process broadening in experimental diabetic nephropathy: Amelioration with renin-angiotensin blockade. Diabetologia 2001 44 : 878 882.
42. Davis BJ, Cao Z, de Gasparo M, Kawachi H, Cooper ME, Allen TJ. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: Potential role of nephrin. J. Hypertens. 2003 21 : 209 216.
43. Miyata T, van Ypersele de Strihou C, Ueda Y et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J. Am. Soc. Nephrol. 2002 13 : 2478 2487.
44. Forbes JM, Cooper ME, Thallas V et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002 51 : 3274 3282.
45. Izuhara Y, Nangaku M, Inagi R et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J. Am. Soc. Nephrol. 2005 16 : 3631 3641.
46. Nangaku M. Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J. Am. Soc. Nephrol. 2006 17 : 17 25.